Dyslipidemia in diabetic nephropathy and hypertension

Themeli, Yllka; Muka, Lutfie; Teferici, Daniela; Bajrami, Valbona; Idrizi, Alma; Barbullushi, Myftar; Shijaku, Mahmud; Ktona, E.; Agaçi, F.

doi:10.1016/j.ijcard.2011.08.561

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with GLP-1 receptor agonists also mildly reduces total and LDL cholesterol and triglycerides [ 125 ]. Diabetic dyslipidemia is not only a consequence of kidney dysfunction, but the underlying condition in the pathogenesis and progression of diabetic nephropathy; furthermore, levels of serum triglyceride, and total and LDL cholesterol, are high in subjects with diabetic nephropathy compared to control subjects [ 126 , 127 ].…”

Section: Introductionmentioning

confidence: 99%

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

Bulum

2022

Biomedicines

View full text Add to dashboard Cite

Diabetes mellitus is the leading cause of chronic kidney disease, and about 30–40% of patients with diabetes will develop kidney disease. Incretin hormones have received attention during the past three decades not only as a pharmacotherapy for the treatment of type 2 diabetes, but also for their cardiorenometabolic effects. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Additional to the pancreas, receptors for GLP-1 are widely distributed in various organs, causing positive effects on endothelial function and vascular atherogenesis. Along with glycemic control and weight reduction, GLP-1 receptor agonists also strongly improve cardiovascular and renal outcomes in patients with type 2 diabetes. Recently, a dual GIP and GLP-1 receptor agonist has been approved for the treatment of type 2 diabetes. Compared to GLP-1 receptor agonist semaglutide, dual GIP and GLP-1 receptor agonist tirzepatide showed a superior reduction in hemoglobin A1c and body weight. Preliminary results also suggest that tirzepatide improves kidney outcomes in adults with type 2 diabetes with increased cardiovascular risk. In this review, we present the nephroprotective properties of dual GIP and GLP-1 receptor agonists as a new drug to treat type 2 diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%